Two Peptides, Two Approaches to Cognition
Selank and Semax are frequently mentioned together, but their mechanisms are fundamentally different. Both were developed at the Institute of Molecular Genetics (Russian Academy of Sciences) and have been approved in Russia as nasal peptide preparations. For researchers worldwide, they represent two distinct approaches to studying cognitive and neuroprotective pathways.
Key Takeaway
Selank targets anxiety-related GABA pathways; Semax targets cognitive enhancement via BDNF and neurotrophic factor modulation. They complement rather than overlap.
Selank: The Anxiolytic Pathway
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is derived from the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro tail that increases metabolic stability. Its primary research interest lies in anxiolytic properties:
- GABA-A receptor modulation — Selank appears to influence benzodiazepine binding sites on GABA-A receptors without producing sedation or dependence-associated effects seen with classical benzodiazepines
- Monoamine modulation — Published research reports effects on serotonin, dopamine, and norepinephrine metabolism in brain regions associated with anxiety
- Immunomodulation — Through its tuftsin-derived structure, Selank retains immunomodulatory properties, including effects on IL-6 and TNF-alpha expression
Semax: The Cognitive Enhancement Pathway
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is based on the ACTH(4-7) fragment — the portion of adrenocorticotropic hormone associated with cognitive effects, separated from the steroidogenic activity of the full ACTH molecule:
- BDNF expression — Semax upregulates Brain-Derived Neurotrophic Factor, a key mediator of neuronal plasticity and memory consolidation
- NGF modulation — Research shows effects on Nerve Growth Factor pathways, supporting neuronal survival and differentiation
- Neuroprotection — Published studies explore Semax's effects in ischemic brain injury models, with data suggesting reduced infarct volume and improved functional outcomes
Head-to-Head Comparison
| Property | Selank | Semax |
|---|---|---|
| Parent molecule | Tuftsin | ACTH(4-7) |
| Primary research focus | Anxiolytic | Nootropic / Neuroprotective |
| Key pathway | GABA-A modulation | BDNF / NGF upregulation |
| Administration route | Intranasal (most studied) | Intranasal (most studied) |
| Immunomodulatory | Yes (tuftsin-derived) | Minimal |
| Sedation risk | Low (no classical BZD activity) | None reported |
For research purposes only. Not for human consumption.